Two Or More Separate Aryl-o-groups Patents (Class 514/734)
  • Patent number: 10251848
    Abstract: In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: April 9, 2019
    Assignee: SINTETICA S.A.
    Inventors: Augusto Mitidieri, Elisabetta Donati, Nicola Caronzolo
  • Patent number: 10053407
    Abstract: Solid cannabidivarin, crystalline cannabidivarin, (R,R)-(?)-crystalline cannabidivarin, (S,S)-(+)-crystalline cannabidivarin and substantially pure forms thereof are disclosed herein. Further disclosed are methods of making such cannabidivarin, compositions and formulations comprising such cannabidivarin, and methods of treating disease with such cannabidivarin.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 21, 2018
    Assignee: S&B Pharma, Inc.
    Inventors: Daniel Dickman, Emerich Eisenreich, Daniel Levin, Mackenzie Marrs
  • Patent number: 9381246
    Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated with Tarceva or other therapeutic compounds and relapsed or are resistant to treatment. The compounds described herein may exhibit a synergistic effect when administered with another agent.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: July 5, 2016
    Assignee: Triact Therapeutics, Inc.
    Inventors: Thomas F. White, Dan Hoth
  • Patent number: 9370474
    Abstract: The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: June 21, 2016
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Kalonda Tymika Johnson, John Lemmo, Michael Southall, Ping Wen
  • Patent number: 9314437
    Abstract: The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: April 19, 2016
    Assignee: NAPO PHARMACEUTICALS, INC.
    Inventor: Pravin R. Chaturvedi
  • Patent number: 9198879
    Abstract: The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: December 1, 2015
    Assignee: NAPO PHARMACEUTICALS, INC.
    Inventor: Pravin R. Chaturvedi
  • Patent number: 9029320
    Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Red Mountain Med Spa, LLC
    Inventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
  • Patent number: 8999399
    Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.
    Type: Grant
    Filed: November 14, 2009
    Date of Patent: April 7, 2015
    Assignee: Bose Chemie GmbH
    Inventors: Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
  • Patent number: 8980851
    Abstract: Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: March 17, 2015
    Assignee: Accelalox, Inc.
    Inventor: James Patrick O'Connor
  • Publication number: 20150057320
    Abstract: A method for treating a disease characterized by excessive lipofuscin accumulation in the retina of a mammal afflicted therewith comprising administering to the mammal an effective amount of a transthyretin (TTR) ligand.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventor: Konstantin PETRUKHIN
  • Publication number: 20150045449
    Abstract: The present invention relate to a highly efficient and novel method, using clean technologies, for obtaining a natural bioactive concentrate that is rich on polyphenols from olive mill water (OMW). The clean technologies integrate centrifugation, a drowning-out crystallization-based separation process, and vacuum evaporation. The method provides a highly-concentrated polyphenol isolate (up to 99% (mass fraction)) from other components presents in OMW, with up to half of the polyphenol content being hydroxytyrosol. The isolated polyphenols exhibit anti-oxidant, anti-microbial, anti-inflammatory, and anti-carcinogenic activities; they can be prepared as solid particles, as an aqueous solution, in an emulsion, or as lipidic-based nanoparticles. The isolated polyphenols can be used in the food industry, cosmetic industry, or pharmaceutical industry.
    Type: Application
    Filed: August 9, 2013
    Publication date: February 12, 2015
    Applicants: Center of Biotechnology of Sfax, University of Sfax, MESRS, UNIVERSITY OF TSUKUBA
    Inventors: Mitsutoshi Nakajima, Marcos Neves, Hiroko Isoda, Ilyes Dammak, Sami Sayadi
  • Publication number: 20150038591
    Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of tauopathies, such as Alzheimer's disease and Parkinson's disease, and the manufacture of medicaments for such treatment.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 5, 2015
    Inventors: Alan D. Snow, Judy A. Cam, Gerardo Castillo, Qubai Hu, Thomas Lake
  • Publication number: 20150025104
    Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.
    Type: Application
    Filed: July 16, 2013
    Publication date: January 22, 2015
    Applicant: BIOACTIVES LLC
    Inventors: Doddabele L. Madhavi, Daniel I. Kagan
  • Publication number: 20150011604
    Abstract: Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 8, 2015
    Applicant: ProteoTech Inc.
    Inventors: Esposito A Luke, Marisa C Yadon, Joel Cummings, F Michael Hudson, Thomas Lake, Qubai Hu, Judy Cam, Alan D. Snow
  • Publication number: 20140378424
    Abstract: The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (ERM), optionally, in combination with an anti-obesity or weight loss agent.
    Type: Application
    Filed: December 31, 2012
    Publication date: December 25, 2014
    Inventors: Alexey G Ryazanov, Alexander V. Chikunov
  • Publication number: 20140370101
    Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 18, 2014
    Applicant: XI'AN LIBANG PHARMACEUTICAL CO., LTD
    Inventors: Rutao Wang, Tao Chen, Shupan Guo, Huijing Hu, Long An, Weijiao Wang
  • Patent number: 8906960
    Abstract: A transdermal fluid is provided wherein the main ingredient is tocotrienol and curcumin is added to enhance the anti-cancer effects of tocotrienols. The composition is useful for the treatment or prevention of a cancer, a tumor or an inflammatory disorder, particularly breast cancer.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: December 9, 2014
    Assignee: Malaysian Palm Oil Board
    Inventors: Kalanithi Nesaretnam, Kanga Rani Selvaduray
  • Patent number: 8889744
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are hexafluoro-honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative hexafluoro-honokiol analogs include hexafluoro-honokiol, analogs in which one or both hydroxy groups are replaced with dichloroacetate esters, and analogs with increased fluorination. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: November 18, 2014
    Inventor: Jack L. Arbiser
  • Publication number: 20140336259
    Abstract: The present document describes a phytochemical isolated from maple syrup and composition comprising the same. More specifically, the document describes an antioxidant phytochemical compound, derivates thereof, and composition comprising the same. The document also describes a process of synthesizing the antioxidant phytochemical compound.
    Type: Application
    Filed: June 11, 2012
    Publication date: November 13, 2014
    Inventors: Navindra Seeram, Julie Barbeau, Genevieve BeLand, Keykavous Parang
  • Publication number: 20140328772
    Abstract: A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol and a sorbitan ester. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti -bacterial activity and reducing the expression of pro-inflammatory mediators. If isopropyl is selected, then the sorbitan ester is at least one of polyoxyethylene 20 sorbitan monooleate, and a proviso that if isobutyl magnolol is selected, then the sorbitan ester is poloxyethylene 20 sorbitan monooleate.
    Type: Application
    Filed: December 15, 2011
    Publication date: November 6, 2014
    Applicant: COLGATE-PALMOLIVE COMPANY
    Inventors: Regina Hourigan, Jeffrey Mastrull, Jairajh Mattai, James Masters
  • Patent number: 8841348
    Abstract: Compositions containing apocynin and paeonol. The compositions may be used for the treatment of inflammatory diseases.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: September 23, 2014
    Assignee: AKL Inflammatory Limited
    Inventor: Nicholas John Larkins
  • Patent number: 8815955
    Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: August 26, 2014
    Assignee: Kemin Industries, Inc.
    Inventor: Richard Roberts
  • Publication number: 20140234232
    Abstract: Described herein are compositions comprising antibacterially effective amounts of a compound of Formula (I): or a salt thereof in which R1 and R2 are each independently (C1-C6) alkyl or (C2 C6) alkenyl, and a carrier. Suitable carriers include orally acceptable carriers and dermatologically acceptable carriers. The disclosed compositions include oral care and personal care compositions useful for treating or preventing oral and skin conditions, respectively.
    Type: Application
    Filed: September 8, 2011
    Publication date: August 21, 2014
    Applicant: Colgate-Palmolive Company
    Inventors: Ravi Subramanyam, Neelima Utgikar, Guofeng Xu, Ying Yang, Lin Fei
  • Publication number: 20140235714
    Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicant: TriAct Therapeutics, Inc.
    Inventors: Thomas F. WHITE, Edward F. SCHNIPPER, Dan HOTH
  • Publication number: 20140221384
    Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: ERIMOS PHARMACEUTICALS LLC
    Inventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
  • Patent number: 8785471
    Abstract: Preparation and usage of a pharmaceutical composition containing ferulic acid and matrine compounds are described. The ingredients ferulic acid and matrine compounds in this pharmaceutical composition have synergistic effects which can obviously improve the pharmacology effects of both the ferulic acid and matrine compounds. Moreover, the pharmaceutical composition can significantly increase the aqueous and fat solubility of the individual ingredients.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: July 22, 2014
    Assignee: Qingdao Qiyuan Bio-Technologies Co., Ltd.
    Inventors: Xiaojie Sun, Weifu Ma
  • Patent number: 8754133
    Abstract: A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where: R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group and pharmaceutically acceptable esters or salts of the compounds and wherein the inflammatory process results from a disease selected from the group consisting of ulcerative colitis, endotoxic shock, rheumatoid arthritis, juvenile arthritis, osteoarthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, gout, psoriatic arthritis, reactive arthritis, vital or post-viral arthritis and an
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: June 17, 2014
    Assignee: ProteoTech, Inc.
    Inventors: Virginia Sanders, Joel Cummings, Alan D Snow
  • Publication number: 20140142067
    Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 22, 2014
    Applicant: BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
    Inventors: Aviv GAZIT, Shimon SLAVIN, Esther PRIEL, Sara YITZCHAK
  • Patent number: 8715632
    Abstract: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: May 6, 2014
    Inventor: S. Katharine Presty
  • Patent number: 8710104
    Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: April 29, 2014
    Assignee: Triact Therapeutics, Inc.
    Inventors: Thomas F. White, Edward F. Schnipper, Dan Hoth
  • Publication number: 20140080920
    Abstract: The invention relates to the identification and the use of compounds which activate the expression of at least one gene selected from LARGE, HS6ST2 and ST8SIA1, for preventing and/or attenuating ageing, and/or for hydrating skin. The invention thus relates to an in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin, and/or for hydrating the skin, including the following steps: a. bringing at least one test compound in contact with a sample of keratinocytes; b. measuring the expression of at least one gene selected from LARGE, HS6ST2 and ST8SIA1, in the keratinocytes; c. selecting the compounds for which an activation of at least 1.4 fold of the expression of at least one of the genes is measured in the keratinocytes treated in a. compared with the untreated keratinocytes.
    Type: Application
    Filed: May 15, 2012
    Publication date: March 20, 2014
    Applicant: CHANEL PARFUMS BEAUTE
    Inventors: Elena Fedorova, Christelle Lasserre
  • Publication number: 20140051751
    Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicants: The Board of Regents of the University of Texas System, University of North Texas Health Science Center at Fort Worth
    Inventors: John A. Schetz, Robert F. McMahon
  • Patent number: 8652444
    Abstract: Antiplaque oral compositions are provided that contain an orally acceptable carrier and an antibacterial effective amount of the compound of formula (I). In various embodiments, the compositions contain from about 0.001% to about 10% by weight of the compound of formula (I).
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: February 18, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Ravi Subramanyam, Prem Sreenivasan
  • Patent number: 8653145
    Abstract: The present invention is a method for alleviating at least one climacteric symptom in a climacteric subject using an anticholinergic agent. To illustrate the instant invention, homatropine was shown to relieve hot flushes in peri-menopausal and post-menopausal women.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: February 18, 2014
    Assignee: Eaton Scientific Systems, Ltd.
    Inventors: Hootan Melamed, Edward Withrow, III, Jennifer Berman
  • Patent number: 8629174
    Abstract: The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and/or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of CE or CE-Q conjugates.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: January 14, 2014
    Assignee: Prevention L.L.C.
    Inventors: Ercole L. Cavalieri, Eleanor G. Rogan
  • Publication number: 20140011890
    Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuin AMPK activity, LKB1 activity and/or CaMKK? activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 9, 2014
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Jeffrey Milbrandt, Biplab Dasgupta
  • Patent number: 8604087
    Abstract: Disclosed is a composition for treating or preventing amyloid-related diseases including 4-O-methylhonokiol as an active ingredient. More specifically, a pharmaceutical composition including 4-O-methylhonokiol, which is effective for treating or preventing amyloid-related diseases such as Alzheimer's disease, cognitive disorder, defective memory, amyloidosis, etc. is disclosed. The inventors of the present disclosure have found out for the first time that 4-O-methylhonokiol inhibits the production of ?-amyloid. It has been confirmed to be useful in treating or preventing amyloid-related diseases. Through animal tests including water maze test and passive avoidance test on mice, 4-O-methylhonokiol has been confirmed to be effective for amyloid-related diseases such as Alzheimer's disease, defective memory, cognitive disorder, and the like.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: December 10, 2013
    Assignee: Bioland Ltd.
    Inventors: Ki Ho Kim, Ki Soo Kim, Young Heui Kim, Jin Guk Kim, Kyoung Tae Kim, Chang Sung Han, Sang iL Lee
  • Publication number: 20130316985
    Abstract: A pharmaceutical composition including at least one compound of the Formulas (I), (II), or (III), or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, as defined herein. Also disclosed is a method of treatment of diseases which are pathophysiologically related to GPR35, the GPR35-hERG signaling complex, or both, as defined herein.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 28, 2013
    Applicant: Corning Incorporated
    Inventors: Huayun Deng, Ye Fang
  • Publication number: 20130274346
    Abstract: The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.
    Type: Application
    Filed: June 6, 2013
    Publication date: October 17, 2013
    Applicant: NAPO PHARMACEUTICALS, INC.
    Inventor: Pravin R. CHATURVEDI
  • Publication number: 20130272974
    Abstract: The present invention provides a granule powder product containing a minimum of 25% Hydroxytyrosol, and a method of making such a product. The product is made from cultivated olive leaves. Because of unique production and purification technology provided by the present invention, Oleuropein present in the olive leaf extract is essentially completely transferred into Hydroxytyrosol by a biotransformation process. As a result, essentially no Oleuropein residue is present in the final product.
    Type: Application
    Filed: April 12, 2012
    Publication date: October 17, 2013
    Inventor: Ahmad Alkayali
  • Patent number: 8551458
    Abstract: The invention relates to a composition in the form of an oil-in-water emulsion containing an ester of fatty acid and of polyethylene glycol, an additional surfactant chosen from esters of C16-C22 fatty acid and of sorbitan and esters of C16-C22 fatty acid and of glycerol, a polycondensate of ethylene oxide and of propylene oxide consisting of polyethylene glycol and polypropylene glycol blocks, and a hydroxylated diphenylmethane derivative. The composition has good stability, in particular after 24 hours at 55° C. Application in caring for and making up keratinous substances.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: October 8, 2013
    Assignee: L'Oreal
    Inventors: Aldo Monello, Melanie Achram
  • Patent number: 8545906
    Abstract: A composition-of-matter comprising a substance usable in producing packaging material and at least one compound selected from the group consisting of ar-turmerone, a sesquiterpene alcohol and a turmeric oleoresin solid residue.
    Type: Grant
    Filed: May 31, 2010
    Date of Patent: October 1, 2013
    Assignees: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center), Biopack Ltd.
    Inventors: Shlomo Navarro, Simcha Finkelman, Dov Zehavi, Refael Dias, Sam Angel, Fadel Mansur, Miriam Rindner
  • Publication number: 20130243886
    Abstract: The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.
    Type: Application
    Filed: September 9, 2011
    Publication date: September 19, 2013
    Applicant: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony RM Coates
  • Publication number: 20130245109
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: June 1, 2012
    Publication date: September 19, 2013
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Publication number: 20130230580
    Abstract: Provided are therapeutics, uses and methods in which neuro-regenerative therapy using neuroprotective agents, or anti-neuropathic agents, to prevent loss or restore hematopoietic capacity and progenitor mobilization.
    Type: Application
    Filed: September 14, 2011
    Publication date: September 5, 2013
    Inventors: Paul S. Frenette, Daniel Lucas-Alcaraz
  • Patent number: 8496979
    Abstract: Disclosed herein are caffeine-free dietary supplements for increasing energy in a subject and methods of administering the same. The method comprises administering to a subject a caffeine-free dietary supplement comprising omega-3 fatty acids, resveratrol, beta-alanine, gamma aminobutyric acid, and valerian root extract product, in amounts such that the supplement is effective for increasing energy and mental focus and relieving stress in the subject.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: July 30, 2013
    Assignee: Reliv International, Inc.
    Inventor: Carl W. Hastings
  • Patent number: 8486997
    Abstract: An external preparation for skin containing an alkylresorcinol and being excellent in temperature stability (especially high-temperature stability) and photostability. More particularly an external preparation for skin comprising (a) from 0.01 to 5% by mass of 4-isobutyl resorcinol or a salt thereof, and (b) from 0.01 to 5% by mass of one or more selected from L-ascorbic acid or a salt thereof and a 3-O-alkyl-L-ascorbic acid or a salt thereof. If desired, (c) one or more compounds selected from (c-1) a sterol skeleton-having compound (e.g., POE phytosterols, POE cholestanols), (c-2) a vitamin E derivative, (c-3) a compound such as polyglycerin fatty acid esters, polyoxybutene-polyglycerin alkyl ethers, sucrose fatty acid esters, and (c-4) a sorbitan skeleton-having compound may be incorporated in the preparation.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: July 16, 2013
    Assignee: Shiseido Company
    Inventors: Keisuke Shinto, Takayuki Sakiguchi, Kazuhiko Fujiwara
  • Publication number: 20130178537
    Abstract: Hydroxytyrosol extracted from olives and/or from the solid residues of olives after the extraction of olive oil, by acid hydrolysis and purification on resin columns eluted with water contains hydroxytyrosol and tyrosol, is free from sugars, has a residual content of Benzo[a]pyrene that is less than 2 microg/Kg (weight BaP/weight of extract as dry matter), containing a weight ratio of hydroxytyrosol to hydroxymethylfurfural of between 45:1 and 10000:1, and the content of hydroxytyrosol in the extract is at least 0.5% (w/w) with purity of at least 40% (by HPLC 280 nm).
    Type: Application
    Filed: July 6, 2012
    Publication date: July 11, 2013
    Applicant: Probelte Pharma, S.A.
    Inventors: Jose A. Lopez Mas, Sergio A. Streitenberger, Marcos Penalver Mellado, Pedro Martinez Ortiz
  • Patent number: 8476248
    Abstract: The present invention provides products having resveratrol with high water solubility and nutraceutical and/or phytotherapic compositions having said substances. The processes for obtaining them include the solubility increase of the polyphenol corresponding to a resveratrol compound, preferably trans-resveratrol in water, by its complexation with cyclodextrin under specific conditions that favor thermodynamic equilibrium. The products of the invention present high solubility and purity in aqueous medium, being, therefore, useful to prepare nutraceutical compositions (pharmaceutical and/or alimentary) with antioxidant, anti-inflammatory, antiviral, antidiabetics, cardioprotective, neuroprotective, chemoprotective activities; besides protecting against infections and ischemia, reducing obesity, and preventing aging.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: July 2, 2013
    Assignees: Uniao Brasileira de Educacao e Assistencia—Mantenedora da PUCRS, Eurofarma Laboratorios Ltda.
    Inventor: Andre Arigony Souto
  • Publication number: 20130109747
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 2, 2013
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle